Posted inBiotechnology
Chutes & Ladders—Former CBER chief Peter Marks leaps to Lilly
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inBiotechnology
Expedition resupplies for phase 2 COPD voyage with $165M series A
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9.…
Posted inBiotechnology
Ono’s BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.…
Posted inMedical Technology
Thermo Fisher rolls out biopsy test to better assess lung transplant rejection risk
Thermo Fisher Scientific has launched a new diagnostic test to help physicians better detect and manage lung transplant rejection. Dubbed…
Posted inBiotechnology
AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413M
England's AviadoBio is looking to China as a potential source of additional gene therapies, securing an option to a $413…
Posted inBiotechnology
Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche…
Posted inBiotechnology
CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug
Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate…
Posted inBiotechnology
US government pumps money toward in vivo cell therapy programs
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into…
Posted inBiotechnology
Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk
New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated with Alzheimer’s disease. Amongst…
Posted inMedical Technology
BD, Opentrons Labs enter multi-year collaboration to join cell analysis, automation tech
Under a multi-year deal, medtech company BD and lab automation specialist Opentrons Labworks are joining forces to leverage their respective…